In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States.
In vitro susceptibility testing of 2,797 group A streptococcus (GAS) isolates demonstrated that telithromycin was fully active against all macrolide-susceptible strains and among 80 of 115 macrolide-resistant GAS expressing the M phenotype. Telithromycin resistance was identified in 2 of 45 strains expressing the inducible macrolide-lincosamide-streptogramin B phenotype and four of nine isolates expressing the constitutive macrolide-lincosamide-streptogramin B resistance phenotype.
Green
Michael
M
Department of Pediatrics, MPH Division of Allergy, Immunology and Infectious Diseases, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA. michael.green@chp.edu
Allen
Coburn
C
Bradley
John
J
Dashefsky
Barry
B
Gilsdorf
Janet R
JR
Marcon
Mario J
MJ
Schutze
Gordon E
GE
Smith
Clay
C
Walter
Emmanuel
E
Martin
Judith M
JM
Edwards
Kathryn A
KA
Barbadora
Karen A
KA
Rumbaugh
Renee M
RM
Wald
Ellen R
ER
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D006801:Humans; D048628:Ketolides / Q000494:pharmacology*; D018942:Macrolides / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D010614:Pharynx / Q000382:microbiology*; D013297:Streptococcus pyogenes / Q000187:drug effects* / Q000302:isolation & purification; D014481:United States
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin